GRP Inhibitors Mitigating Influenza Lung Damage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for influenza infections are limited in effectiveness, particularly in reducing virally-induced lethality and lung inflammation, as they often require early administration and are hindered by viral mutation and resistance, necessitating alternative therapeutic strategies that modulate the host's innate immune response.
Innovation Solution
The use of GRP inhibitors and GRPR antagonists, such as monoclonal antibodies and small-molecule inhibitors, to target and reduce GRP activity in the lungs, thereby mitigating inflammatory responses and lung damage during influenza infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for influenza infections are used, then viral clearance may be achieved, but effectiveness is limited due to early administration requirement and viral mutation resistance
Solution Approach 1:
The patent converts the harmful excessive inflammatory response caused by GRP into a beneficial target for therapy. By using GRP inhibitors and GRPR antagonists to block the harmful inflammatory cascade, the treatment transforms the pathogenic mechanism into a therapeutic target, achieving effectiveness against diverse influenza strains including mutated variants
2Object-affected harmful factors
If GRP inhibitors or GRPR antagonists are administered, then lung inflammation and lethality are reduced, but the mechanism involves modulating host immune response rather than direct antiviral action
Solution Approach 1:
The patent uses GRP inhibitors and GRPR antagonists as intermediary agents that mediate between the host's immune response and the pathological outcome. These compounds do not directly kill the virus but intervene in the GRP-GRPR signaling pathway to prevent excessive inflammation, serving as a bridge that modulates the host response to protect against lung damage and lethality
3Reliability
If conventional antiviral treatments are used, then direct viral inhibition is achieved, but treatment window is limited requiring early administration
Solution Approach 1:
The patent employs GRP inhibitors and GRPR antagonists that can be administered as preliminary protective measures or early in the disease course to prevent the development of severe inflammation. By blocking the GRP-GRPR pathway before excessive inflammatory damage occurs, the treatment creates a protective effect that extends the effective treatment window beyond the narrow window required for conventional antivirals
Data Source
Figure 1a~2c
Figure 3a~3e
Figure 4a~4g
AI summary
Gastrin–releasing peptide (GRP) is a neuroendocrine peptide that acts as a novel contributor to the inflammatory response to influenza infection. Thus, inhibition of GRP or antagonizing the GRP receptor (GRPR) during influenza infection represents a novel therapeutic approach to mitigating lung damage. The present invention encompasses methods of treatment based on these novel findings and observations.